Otsuka Notches IgAN Win as FDA Approves First Anti-APRIL Antibody
Analysts at Guggenheim Partners expect Voyxact to see “broad commercial uptake” given its relatively broad label compared with previous accelerated approvals for IgA nephropathy.
Otsuka Notches IgAN Win as FDA Approves First Anti-APRIL Antibody Read More »
